Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): A model for prospective comparison of cooperative group trials.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Clinical Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/jco.2004.22.14_suppl.7007PMID 28016289
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Different treatment efficacies and side effects of cytotoxic chemotherapy

  2020influential citation
• A Comparison of White and African American Outcomes from a Three-Arm, Randomized, Phase III Multicenter Trial of Advanced or Metastatic Non-small Cell Lung Cancer

  2010cites this paper
• Phase I study of TLR9 agonist PF‐3512676 in combination with carboplatin and paclitaxel in patients with advanced non‐small‐cell lung cancer

  2010cites this paper
• Uncovering Disparities in Survival after Non–Small–Cell Lung Cancer among Asian/Pacific Islander Ethnic Populations in California

  2009influential citation
• Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing

  2008cites this paper
• Triple Combination Chemotherapy with Cisplatin, Docetaxel, and Irinotecan for Advanced Non-small Cell Lung Cancer: A Phase I/II Trial

  2007cites this paper
• Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer

  2006cites this paper
• A Phase II Randomized Study of Paclitaxel Plus Carboplatin or Cisplatin against Chemo-Naive Inoperable Non-small Cell Lung Cancer in the Elderly

  2006cites this paper
• Recent trends in the treatment of advanced lung cancer

  2006cites this paper
• A review of the benefit–risk profile of gefitinib in Asian patients with advanced non‐small‐cell lung cancer

  2006cites this paper
• Advances in our understanding of postoperative adjuvant chemotherapy in resectable non-small-cell lung cancer

  2006cites this paper
• Interstitial Lung Disease in Japanese Patients With Non‐Small Cell Lung Cancer Receiving Gefitinib: An Analysis of Risk Factors and Treatment Outcomes in Okayama Lung Cancer Study Group

  2005cites this paper